Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Blog|Videos|February 24, 2023

A Quiet Life

Author(s)Richard M. Berlin, MD

"This isn’t as easy as it seems..."

Any Good Poem

Richard Berlin, MD, shares Baron Wormser's poem "A Quiet Life," which highlights how simple things, even an egg, connect us all.

Dr Berlin has been writing a poem about his experience of being a doctor every month for the past 25 years in Psychiatric Times™ in a column called “Poetry of the Times.” He is instructor in psychiatry, University of Massachusetts Medical School, Worcester, Massachusetts. His latest book is Freud on My Couch.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

beach

The Night We Heard Ella Sing

ByRichard M. Berlin, MD

August 13th 2026

sandbox

My Barbaric Yawp

ByRichard M. Berlin, MD

June 16th 2026

listening

Listening

ByRichard M. Berlin, MD

May 13th 2026

body scan

"Paraganglioma in the Organ of Zuckerkandl"

ByRichard M. Berlin, MD

April 17th 2026

cat scan

Paraganglioma in the Organ of Zuckerkandl

ByRichard M. Berlin, MD

April 16th 2026

Latest CME

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Trending on Psychiatric Times

When Treatment-Resistant Depression Means Mismatched: Rethinking Difficult-to-Treat Depression

August 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News

Presenting Our September 2026 Theme: Depressive Disorders

Phase 2 Trial of Bezisterim for Neurological Symptoms of Long COVID: Treatment Phase Completed

Novel Serotonergic Agonist, HLP003, Targets the Adjunctive MDD Treatment Gap